63
Participants
Start Date
September 30, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
June 30, 2015
PPX (CT2103)
XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
Temozolomide
XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
SUNY Medical Center, Syracuse
PSU, Hershey
Thomas Jefferson University Cancer Center, Philadelphia
UT Southwestern Cancer Center, Dallas
UCSD Cancer Center, La Jolla
University of Washington, Seattle
Maine Medical Center, Scarborough
UMASS Medical Center Cancer Center, Worcester
Rhode Island Hospital, Providence
Lead Sponsor
Collaborators (1)
Rhode Island Hospital
OTHER
Milton S. Hershey Medical Center
OTHER
University of Washington
OTHER
University of Massachusetts, Worcester
OTHER
MaineHealth
OTHER
University of California, San Diego
OTHER
Thomas Jefferson University
OTHER
Brown University
OTHER